The DOI matches its Crossref record.
A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation
Open accessAbstract
Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([131I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post-OLT antirecurrence efficacy of Licartin in advanced HCC patients. We randomized 60 post-OLT patients with HCC, who were at tumor stage 3/4 and outside the Milan criteria before OLT, into 2 groups. Three weeks after OLT, the treatment group received 15.4 MBq/kg of Licartin, while the control group received placebo intravenously for 3 times with an interval of 28 days. At 1-year follow-up, the recurrence rate significantly decreased by 30.4% ( P = 0.0174) and the survival rate increased by 20.6% ( P = 0.0289) in the treatment group, compared with those in the control group. For the control group versus the treatment group, the hazard ratio for recurrence was 3.60 (95% confidence interval [CI], 1.50-8.60) and that for death was 3.87 (95% CI, 1.23–12.21). Licartin treatment also resulted in an earlier decreased AFP level and a longer time of normal AFP level than placebo ( P = 0.0016). No Licartin-related toxic effects were observed. Conclusion: Licartin is a promising drug for preventing post-OLT tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT. HAb18G/CD147 can be a good drug target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis and Treatment of Hepatocellular Carcinoma
El-Serag, H. B., Marrero, J. A., Rudolph, L., & Reddy, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.090 · Cited by 1,137
Clavien, P.-A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,026
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Self-citationMehta, N., Heimbach, J., Harnois, D. M., Sapisochin, G., Dodge, J. L., Lee, D., Burns, J. M., Sanchez, W., Greig, P. D., Grant, D. R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5116 · Cited by 398
Lactic Acid: No Longer an Inert and End-Product of Glycolysis
Sun, S., Li, H., Chen, J., & Qian, Q. (2017) · Physiology · doi:10.1152/physiol.00016.2017 · Cited by 314
Metadata
- Authors
- Xu, J., Shen, Z.-Y., Chen, X.-G., Zhang, Q., Bian, H.-J., Zhu, P., Xu, H.-Y., Song, F., Yang, X.-M., Mi, L., Zhao, Q.-C., Tian, R., Feng, Q., Zhang, S.-H., Li, Y., Jiang, J.-L., Li, L., Yu, X.-L., Zhang, Z., & Chen, Z.-N.
- Venue
- Hepatology
- Published
- 2007-02
- Volume
- 45
- Issue
- 2
- Pages
- 269-276
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2027549866
- Cited by
- 183
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. https://app.cochat.ai/papers/10.1002/hep.21465
- The paper
- Xu, J., Shen, Z.-Y., Chen, X.-G., Zhang, Q., Bian, H.-J., Zhu, P., Xu, H.-Y., Song, F., Yang, X.-M., Mi, L., Zhao, Q.-C., Tian, R., Feng, Q., Zhang, S.-H., Li, Y., Jiang, J.-L., Li, L., Yu, X.-L., Zhang, Z., & Chen, Z.-N. (2007). A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. https://doi.org/10.1002/hep.21465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.